Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Varian, a Siemens Healthineers Company
Novartis
EMD Serono
AstraZeneca
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
Boehringer Ingelheim
Incyte Corporation
Astellas Pharma Inc
Travera Inc
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Jazz Pharmaceuticals
Novartis
Bayer
Fate Therapeutics
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
858 Therapeutics, Inc.
GlaxoSmithKline
SystImmune Inc.
Terremoto Biosciences Inc.
Orano Med LLC
Seagen Inc.
Filamon LTD
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
Pfizer
AstraZeneca
Hoffmann-La Roche
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
ViroMissile, Inc.
Replimune, Inc.
Yuhan Corporation
Carevive Systems, Inc.
AstraZeneca
Myeloid Therapeutics
Tizona Therapeutics, Inc
MBrace Therapeutics
Angiex, Inc.
New Phase Ltd.